Cancer research advances in small, verified steps, and every so often a conference presentation strings several of them together. At the European Association of Nuclear Medicine congress in Vienna this week, Actinium Pharmaceuticals presented new preclinical results for ATNM-400, its experimental targeted radiotherapy, showing activity across lung, colorectal and ovarian cancer models – three of the hardest territories in oncology.
First, an honest framing, because the numbers deserve it: these are preclinical results, from laboratory cancer models, not yet patient outcomes. ATNM-400 is already in clinical development for prostate cancer, and this week’s data widens the scientific foundation underneath it. What the Vienna presentations showed, across one oral presentation and two e-posters, is a therapy hitting its target in tumor type after tumor type.
What the data showed
ATNM-400 is a first-in-class antibody radioconjugate: an antibody that homes to HER3, a protein found on many tumor cells and linked to treatment resistance, carrying a payload of actinium-225, which delivers high-energy alpha radiation directly into the targeted cell and breaks its DNA in a way conventional drugs cannot easily copy. In ovarian cancer models, it achieved 93 percent tumor growth inhibition on its own, and kept working in models where the standard drug bevacizumab had stopped working. In a poorly responsive colorectal model, adding ATNM-400 to the standard combination of oxaliplatin and bevacizumab lifted tumor growth inhibition from 25 percent to 72 percent. In lung cancer, it showed activity across tumors driven by three different mutations – EGFR, KRAS and ALK – which supports developing it without restricting it to one genetic subtype.
Why the HER3 address matters
Tumors survive by adapting, and HER3 is one of the escape routes they use. A therapy that delivers radiation to any cell displaying that marker does not care which mutation drove the cancer in the first place – the address on the cell surface is enough. That mutation-agnostic logic is what makes a 93 percent inhibition figure in one model and a tripled inhibition rate in another more than a coincidence of good days in the lab. It is the same targeting idea succeeding under different conditions, which is the pattern researchers look for before spending years and fortunes on patient trials.
The week has been full of medicine attacking old problems from new angles, from a Dijon trial clearing its survival bar in colorectal cancer to new tools for sunlight-sensitive patients. ATNM-400’s chapter is earlier in the story – models today, and a clinical program in prostate cancer already under way to learn what it can do in people. But every therapy patients rely on began exactly here, in a conference hall, with numbers strong enough to demand the next step. Vienna just heard a set of numbers that demand it.
The road from models to medicine
What happens next is the disciplined part. Preclinical packages like this one exist to answer a regulator’s and a clinician’s first questions: does the targeting hold across tumor types, does the combination add to standard care rather than merely accompany it, and what dose deserves to go forward. Actinium already operates a clinical-stage program in prostate cancer, which means the company is learning in parallel what actinium-225 conjugates do in actual patients – knowledge that feeds directly back into how these lung, colorectal and ovarian findings get developed.
Patients reading over a researcher’s shoulder should hold two thoughts at once. The first is that no one should plan treatment around a conference abstract; the path from 93 percent inhibition in a model to a medicine on a shelf is measured in years and often fails. The second is that oncology’s real advances have always started as exactly this kind of result – a mechanism that works in more than one setting, reported carefully, at a serious congress. Vienna heard one this week. The scientists in that hall know the difference between a headline and a lead. They applauded a lead.
The Vienna congress itself is part of the story. The European Association of Nuclear Medicine meeting gathers the specialists who actually deliver radiotherapies to patients, which makes it a demanding audience for preclinical claims – these are clinicians who know exactly how far a model result is from a treatment room. Presenting three datasets there, across tumor types that share little except difficulty, was Actinium putting its work in front of the toughest referees available and inviting scrutiny. That confidence matters. Combined with this week’s patient-level progress in Dijon, the picture across oncology right now is of multiple independent approaches – antibodies, radioconjugates, combinations – converging on the same stubborn diseases from different directions. Patients do not care which direction wins. Weeks like this one are how winning starts.
It is worth remembering, amid the celebration, who the numbers are ultimately for. Every percentage of tumor inhibition is a shorthand for someone’s remaining time – time measured in birthdays, anniversaries, ordinary Tuesdays that suddenly feel precious. The scientists in Vienna did not forget that, even in the most technical hour of the conference. Neither should we. Research like this week’s is slow, unglamorous work until the day it is not, and days like this one are why the work continues.
Also published on:
- News Today World – https://newstodayworld.org/breaking-news/2026/10/20/prince-mario-max-schaumburg-lippe-a-targeted-radiotherapy-posts-striking-results-across-three-cancers/
- American Morning Herald – https://americanmorningherald.com/morning-brief-a-radiation-therapy-aimed-at-one-address-hit-three-cancers-in-vien/
- Newsy USA – https://newsyusa.com/a-targeted-cancer-therapy-shines-across-three-hard-cancers-in-vienna/
- The American Newsroom – https://theamericannewsroom.com/in-vienna-a-targeted-radiation-therapy-shows-its-reach-across-three-hard-cancers/
- Revista Minutos – https://revistaminutos.com/una-radioterapia-dirigida-logra-resultados-llamativos-en-modelos-de-tres-tipos-d/
- Le Miroir Français – https://lemiroirfrancais.com/une-radioth-rapie-cibl-e-signe-des-r-sultats-frappants-contre-trois-cancers/
Be First to Comment